Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

NPS Pharmaceuticals Inc (NPSP)

NASDAQ
Currency in USD
Disclaimer
45.97
0.00(0.00%)
Closed
Fair Value
Unlock Value
Day's Range
45.9545.99
52 wk Range
0.0045.99
Prev. Close
45.97
Open
45.96
Day's Range
45.95-45.99
52 wk Range
0-0
Volume
0
Average Vol. (3m)
6,834,819
1-Year Change
0%
Shares Outstanding
108,581,000
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about NPSP?
Vote to see community's results!
or

NPS Pharmaceuticals Inc Company Profile

Shire-NPS Pharmaceuticals, Inc., a biopharmaceutical company, provides therapeutic products for the treatment of gastrointestinal and endocrine disorders. The company offers Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support in the United States; and Revestive for the treatment of adult patients with SBS in the European Union. Its products also include Gattex/Revestive in pediatric SBS; Natpara, a bioengineered replica of human parathyroid hormone to control hypocalcemia in patients with hypoparathyroidism; and Natpar to treat hypoparathyroidism, as well as NPSP795, a calcilytic agent for treating disorders involving increased calcium receptor activity. In addition, the company offers various royalty-based products, such as Sensipar and Mimpara for the treatment of primary and secondary hyperparathyroidism; Sensipa for treating hypercalcemia in parathyroid cancer; REGPARA for the treatment of secondary hyperparathyroidism; and NUCYNTA and Nucynta ER for treating acute pain and chronic pain. The company was formerly known as NPS Pharmaceuticals, Inc. and changed its name to Shire-NPS Pharmaceuticals, Inc. in June 2017. Shire-NPS Pharmaceuticals, Inc. was founded in 1986 and is based in Bedminster, New Jersey. As of February 21, 2015, The company operates as a subsidiary of Shire Pharmaceutical Holdings Ireland Limited.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.